^
Association details:
| Biomarker: | FGFR1 amplification + RAF1 amplification + CDK6 amplification |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC
Excerpt:
...liquid biopsy revealed additional increase of tumor molecular burden (somatic alteration burden, 16.4% v 12.2%), with persistence of FGFR1 amplification and reappearance of RAF-1 amplification, as well as the emergence of CDK6 amplification...Ponatinib was discontinued after 12 weeks because of further disease progression with adrenal metastasis, and nivolumab was started under compassionate use...The patient ultimately died in July 2018 as a result of clinical deterioration and further disease progression.
DOI:
10.1200/PO.19.00243
Test:
